News & Updates
Filter by Specialty:
Fremanezumab eases migraine and depressive symptoms
Treatment with fremanezumab – an anticalcitonin gene-related peptide (CGRP) – reduces depressive symptoms in patients with migraine and comorbid major depressive disorder (MDD) in the UNITE trial.
Fremanezumab eases migraine and depressive symptoms
13 Jul 2023
Urinary CKD273 predicts early renal damage in primary hypertension
A classifier developed based on 273 urinary peptides (CKD273) can predict new-onset proteinuria in patients with primary hypertension and be used to diagnose those with early renal injury, reports a study. This predictor contributes to the early prevention and treatment of hypertensive nephropathy.
Urinary CKD273 predicts early renal damage in primary hypertension
12 Jul 2023
Microencapsulated benzoyl peroxide cream alters skin microbiota, improves rosacea
Treatment with a microencapsulated benzoyl peroxide (E-BPO) 5% cream contributes to changes in the microbiome of the skin and results in improvements in moderate to severe rosacea, according to a study presented at the recent WCD 2023.
Microencapsulated benzoyl peroxide cream alters skin microbiota, improves rosacea
12 Jul 2023
Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy
A prediction model on disease recurrence for low-risk, resected stage I lung adenocarcinoma can classify postoperative patients with available clinical information and may even aid in personalizing a follow-up strategy and future adjuvant therapy, reports a study.
Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy
12 Jul 2023
S-ketamine anaesthesia improves recovery following modified radical mastectomy
A prospective randomized controlled trial of breast cancer (BC) patients undergoing modified radical mastectomy (MRM) finds that S-ketamine used in place of sufentanil for general anaesthesia (GA) improves postoperative recovery.
S-ketamine anaesthesia improves recovery following modified radical mastectomy
12 Jul 2023
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).